Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01693315 · ClinicalTrials.gov registry record · Phase 2
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
A Phase 2 study of Glaucoma and Ocular Hypertension, sponsored by Amakem.
- Completed
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
- 6
- Study locations
NCT01693315 is a Phase 2 study of Glaucoma and Ocular Hypertension that has completed, run by Amakem. The registered enrollment target is 82 participants, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (91% lower). The trial reports 6 study locations across 4 states.
The verdict
NCT01693315, a Phase 2 study of Glaucoma and Ocular Hypertension, has completed, sponsored by Amakem.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
- 6
- Study locations
Study Summary
The objective of this dose-escalation study is to evaluate the safety, tolerability and efficacy of AMA0076 in reduction of intraocular pressure in subjects with ocular hypertension or primary open-angle glaucoma.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AMA0076
Study Locations (6)
California
- Artesia Clinical Site - Site 02 - Artesia
- Inglewood Clinical Site - Site 03 - Inglewood
- Petaluma Clinical Site - Site 05 - Petaluma
Connecticut
- New Haven Clinical Site - Site 01 - New Haven
Georgia
- Atlanta Clinical Site - Site 04 - Atlanta
North Carolina
- High Point Clinical Site - Site 06 - High Point
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2012-09 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01693315
The ClinicalTrials.gov registry entry for NCT01693315 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (91% lower). The listed sponsor is Amakem, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Glaucoma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01693315 reports 6 study locations spanning 4 distinct geographic areas - top geographies include California, Connecticut, Georgia.
Frequently Asked Questions
What is clinical trial NCT01693315 about?
NCT01693315 is a clinical study titled "Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma". The objective of this dose-escalation study is to evaluate the safety, tolerability and efficacy of AMA0076 in reduction of intraocular pressure in subjects with ocular hypertension or primary open-angle glaucoma.
What is the current status of trial NCT01693315?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2012-09. Estimated completion is 2013-07.
What conditions does trial NCT01693315 study?
This clinical trial studies the following conditions: Glaucoma, Ocular Hypertension, Eye Disease.
What interventions are being tested in trial NCT01693315?
The interventions under investigation include: Placebo (DRUG), AMA0076 (DRUG).
Who is sponsoring clinical trial NCT01693315?
This trial is sponsored by Amakem, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01693315 being conducted?
This trial has 6 study locations across California, Connecticut, Georgia, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
RECRUITING · Phase 2
-
Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
RECRUITING · Phase 2
-
Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration
ACTIVE NOT RECRUITING · Phase 2
-
Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma
ACTIVE NOT RECRUITING · Phase 2
-
Circadian Rhythms of Aqueous Humor Dynamics in Humans
COMPLETED · Phase 2
-
A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.